30th week of 2010 patent applcation highlights part 37 |
Patent application number | Title | Published |
20100189738 | PORIN B (PorB) AS A THERAPEUTIC TARGET FOR PREVENTION AND TREATMENT OF INFECTION BY CHLAMYDIA - The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit | 2010-07-29 |
20100189739 | Immunogenic compositions comprising dal/dat double mutant, auxotrophic attenuated strains of Listeria and their methods of use - The invention includes auxotrophic attenuated mutants of | 2010-07-29 |
20100189740 | MODIFIED POLYSACCHARIDES FOR CONJUGATE VACCINES - The present invention relates to methods of manufacture of immunogenic glycoconjugates, in particular for use in pharmaceutical compositions for inducing a therapeutic immune response in a subject. The immunogenic glycoconjugates of the invention comprise one or more oligosaccharides or polysaccharides that are conjugated to one or more carrier proteins via an active aldehyde group. Accordingly, the invention provides methods of making (i) unsaturated microbial N-acyl derivative oligosaccharides or polysaccharides; (ii) novel conjugates of unsaturated N-acyl derivatives; and (iii) glycoconjugate compositions comprising conjugate molecules of fragments of microbial unsaturated N-acyl derivatives that serve as a covalent linker to one or more proteins. The invention further encompasses the use of the immunogenic glycoconjugates pharmaceutical compositions for the prevention or treatment of an infectious disease. | 2010-07-29 |
20100189741 | OIL-IN-WATER EMULSION INFLUENZA VACCINE - The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 μg HA or a low amount such as less than 15 μg HA. | 2010-07-29 |
20100189742 | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines - The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B. | 2010-07-29 |
20100189743 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2010-07-29 |
20100189744 | PAPILLOMAVIRUS VACCINE COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection. | 2010-07-29 |
20100189745 | Production of Viral Vaccine - The present invention relates, in general, to materials and methods for production of an improved vaccine against influenza virus, wherein the vaccine comprises a reassortant virus having a hemagglutinin gene and a neuraminidase gene from the same influenza A virus subtype or influenza B strain of virus and internal genes from a different influenza A virus subtype or influenza B strain of virus. In one aspect, the HA and NA genes and the internal genes are from a highly pathogenic H5N1 strain of influenza A. | 2010-07-29 |
20100189746 | ADAPTATION OF PITMAN MOORE STRAIN OF RABIES VIRUS TO PRIMARY CHICK EMBRYO FIBROBLAST CELL CULTURES - The present invention relates to a process of adaptation of Pitman Moore strain of rabies virus to Primary chick fibroblast cells for the production of rabies vaccine. | 2010-07-29 |
20100189747 | Compositions and methods for treating or preventing hiv infection - The present invention provides methods and compositions for treating and/or preventing HIV infection in a subject in need thereof. It features the use of poxviruses, such as vaccinia virus, for therapy, prophylaxis, and diagnosis of HIV, as well as for any other medical or veterinary use associated with HIV or homologous viruses. The invention also provides for the use of poxviruses in the discovery of new agents to prevent and/or treat HIV infection. | 2010-07-29 |
20100189748 | INACTIVATED STAPHYLOCOCCAL WHOLE-CELL VACCINE - A vaccine is disclosed that is protective against pathogenic bacterial species, typically staphylococcal species, and includes methods to prepare said vaccine and to culture pathogenic bacteria. | 2010-07-29 |
20100189749 | METHODS FOR PRODUCING YEAST-BASED VACCINES - The invention provides methods for culturing yeast at a neutral pH level. Yeast cultured under neutral pH conditions exhibit desirable characteristics useful for biological purposes, such as the development of vaccines, prophylactics and therapeutics. The invention also provides for compositions and kits comprising yeast grown using the methodologies disclosed herein. | 2010-07-29 |
20100189750 | METHODS OF TREATING TUMORS IN IMMUNE-PRIVILEGED SITES - A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject. | 2010-07-29 |
20100189751 | PERCUTANEOUS ABSORPTION TYPE PATCH - A percutaneous absorption type patch adapted to be applied to a skin surface of a patient. The percutaneous absorption type patch comprises: a stratum-corneum release member constituted from a sheet-like first supporting substrate and a pressure-sensitive adhesive layer laminated on the first supporting member; a medicinal-components administration member constituted from a sheet-like second supporting substrate, a medicinal-components retention layer laminated on the second supporting substrate, and a protect layer laminated on the medicinal-components retention layer; and a sheet-like handling member interposed between the stratum-corneum release member and the medicinal-components administration member. An edge portion of the handling member is coupled to or integrated with both the first supporting substrate and the protect layer. Operations of peeling the stratum-corneum release member from the skin surface of the patient and peeling the protect layer from the medicinal-components retention layer are carried out at a time by pulling the handling member toward an operating direction. | 2010-07-29 |
20100189752 | PELLETED MINERAL SUPPLEMENT FOR LAND ANIMALS - A pelleted mineral supplement for land animals is provided. Each of the pellets is a cohesive mass of mineral components that when consumed by a land animal promotes the health and/or growth of the animal, and each of the cohesive masses has a largest dimension less than 0.5 inches. In certain aspects of the invention, the pelleted mineral supplement can be combined with a conventional animal feed to provide a mineral-supplemented animal feed. | 2010-07-29 |
20100189753 | ODOR-CONTROL ARTICLE - A patch for controlling odor that is applied directly to the skin is provided. The patch includes a skin-adherent adhesive layer having a pressure sensitive adhesive and an odor-control agent, and a flexible backing layer. | 2010-07-29 |
20100189754 | Oil Based Composition For External Use On Skin For Enhancing Percutaneous Absorption - An oil based composition for external use on skin for enhancing percutaneous absorption of a water-soluble agent contains 50% by mass to 95% by mass of an oil constituent, which contains 10% by mass to 100% by mass of a solid or semisolid oil constituent, and 5% by mass to 50% by mass of particles. The composition has occlusivity of at least 50% and is adapted for use such that, after a preparation for external use on skin, which preparation contains a water-soluble agent, has been applied onto skin, the composition may be applied onto the preparation for external use on skin, which preparation has been applied onto the skin. A method of enhancing percutaneous absorption of a water-soluble agent utilizes the composition. | 2010-07-29 |
20100189755 | Dryer Sheets and a Method for Treating Skin - The invention relates to substrates impregnated with the skin-treating components which when introduced into a tumbling-type dryer in which it contacts fabric articles, the skin-treating component is transferred to the fabric articles which, when contacted with the skin of a user applies the skin-treating component to human skin. | 2010-07-29 |
20100189756 | SHEET MATERIAL FOR ANTIMICROBIAL OR STERILIZING PURPOSES AND PROCESS FOR MANUFACTURING THE SAME - To provide a material for antimicrobial or sterilizing purposes which can be used for people having delicate skin, such as babies, little children or the aged, without any trouble, which prevents viruses from acquiring tolerance, and which does not affect human bodies or foods. A sheet material for antimicrobial and/or sterilizing purposes having a surface having a plurality of indentations with a pore size of 1000 nm or less. | 2010-07-29 |
20100189757 | DRUG DEPOT IMPLANT DESIGNS AND METHODS OF IMPLANTATION - The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement. | 2010-07-29 |
20100189758 | COATING CONTAINING PEGYLATED HYALURONIC ACID AND A PEGYLATED NON-HYALURONIC ACID POLYMER - Provided herein are a method, which comprises implanting in a patient an implantable device comprising a coating that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof. | 2010-07-29 |
20100189759 | CHEMICAL TREATMENT FOR REMOVING CELLULAR AND NUCLEAR MATERIAL FROM NATURALLY OCCURRING EXTRACELLULAR MATRIX-BASED BIOMATERIALS - A method is provided for sequential decellularization of an isolated tissue using solubilizing solutions comprising at least one oxidizing agent that removes all cellular and nuclear materials from the tissue while substantially maintaining the biological and, mechanical properties, and the biochemical properties of the resulting extracellular matrix. | 2010-07-29 |
20100189760 | Synthetic Cell Platforms and Methods of Use Thereof - The present invention provides synthetic cell platforms. The synthetic cell platforms can be used for culturing cells in vitro. The synthetic cell platforms can also be implanted together with bound cells into an individual. The present invention provides methods of using the platforms to provide cells or progeny of such cells for use in various applications, including clinical applications; and methods of use of the platforms to introduce cells into an individual. | 2010-07-29 |
20100189761 | Methods for Prevention and/or Treatment of Capsular Contracture - Methods for prevention or treatment of capsular contracture following surgical implants and other fibrosis related conditions comprising applying a topical composition comprising a pharmaceutically acceptable keratolytic, a pharmaceutically acceptable protein denaturant, a hydrating agent, and combinations thereof are disclosed. | 2010-07-29 |
20100189762 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases. | 2010-07-29 |
20100189763 | CONTROLLED RELEASE SYSTEMS FROM POLYMER BLENDS - Described herein are improved microparticles. In one aspect, the microparticles comprise a first polymer and a second polymer wherein the second polymer is different than the first polymer. In further aspects, the microparticles comprise a bioactive agent encapsulated therein. | 2010-07-29 |
20100189764 | BIOACTIVE MESH - Surgical meshes include bicomponent fibers and/or microfibers. A bicomponent fiber or microfiber includes a non-absorbable inner core including at least one flexible polymer and an absorbable surface material including at least one rigid polymer. The absorbable surface material has a first stiffness and the non-absorbable inner core has a second stiffness which is lower than the first stiffness. The bicomponent fiber or microfiber surgical mesh is less flexible prior to implantation and more flexible following implantation in tissue. The mesh may be used for the treatment of hernias, vaginal prolapses, and other injuries. | 2010-07-29 |
20100189765 | IMPLANTABLE OCULAR DRUG DELIVERY DEVICE AND METHODS - The present invention provides implantable ocular drug delivery devices. Generally, the devices have a distal portion with a coil shaped body member and a proximal portion which contacts the sclera. In one aspect, the coil-shaped body member includes a unique configuration including two coiled portions with different pitches, which improves insertion of the device into the eye. In another aspect, the device has a proximal portion that includes a unique cap configuration having a concave distal face that improves stabilization of the device in the eye. In another aspect, the device includes a transitional portion between the cap and the coil-shaped body member that also improves stabilization of the device in the eye. The invention also provides methods for inserting the medical device into the eye, and methods for the treatment of an ocular condition. | 2010-07-29 |
20100189766 | SUBSTANCE DELIVERING PUNCTUM IMPLANTS AND METHODS - Substance delivering punctum plug devices and related methods for treating disorders and diseases of the eye. Some embodiments of the device maximize dissolution of the substance in tears and/or other fluid(s) that distribute to the anterior surface of the eye so as to maximize delivery of the substance to or through the cornea or anterior surface of the eye ball while minimizing loss of substance through other routes. | 2010-07-29 |
20100189767 | PROBIOTIC COMPOSITIONS AND METHODS OF MAKING SAME - The present invention provides solid compositions of bioactive agents, in particular of probiotic microorganisms. Furthermore, the present invention provides methods for preparing these compositions. The methods include microencapsulating live microorganisms to produce a dry formulation and optionally coating the microcapsules while retaining to a significant extent the viability of the microorganisms. | 2010-07-29 |
20100189768 | COMPRESSED CHEWING GUM TABLET COMPRISING TASTE-MASKING AGENT - The present invention relates to compressed chewing gum tablets comprising a useful antihistamine. In particular, the present invention is directed to compressed chewing gum tablet, which effectively mask the unpleasant tastes of compound according to formula I, such as cetirizine, contained therein and methods for preparing such compressed chewing gum tablet. | 2010-07-29 |
20100189769 | Polypeptide Films and Methods - Disclosed herein are polypeptide multilayer films wherein a therapeutic agent is covalently linked to a first layer polypeptide. An advantage of such attachment is that the linked therapeutic agent can be controllably released from the multilayer film into the environment of the film upon the addition of a suitable stimulus. An advantage of the disclosed films and methods is enablement of environmentally-stimulated release under specific conditions. | 2010-07-29 |
20100189770 | BIOERODIBLE PATCH - A bioerodible patch comprising at least one bioadhesive layer and at least one non-bioadhesive layer, wherein the bioadhesive layer comprises at least one polyaphron dispersion and at least one bioadhesive polymer, and wherein the polyaphron dispersion comprises at least one pharmaceutically active agent. | 2010-07-29 |
20100189771 | FIXED RATIO DRUG COMBINATION TREATMENTS FOR SOLID TUMORS - Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors. | 2010-07-29 |
20100189772 | Compositions of TLR ligands and antivirals - The invention relates to methods and products for the treatment of viral infection using a combination of anti-viral agents and TLR ligands. The invention also relates to screening assays, associated products, kits, and in vitro methods. | 2010-07-29 |
20100189773 | 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2010-07-29 |
20100189774 | FORMATION OF PROTEOLIPOSOMES CONTAINING MEMBRANE PROTEINS BY MEANS OF AN ACELLULAR PROTEIN SYNTHESIS SYSTEM - This invention concerns a process for obtaining proteoliposomes containing membrane proteins. This process is characterized by lipid vesicles being incubated in the reaction medium of an in vitro cell-free protein transcription/translation system. | 2010-07-29 |
20100189775 | PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL KIT FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA - The present invention provides pharmaceutical compositions for the treatment of hepatocellular carcinoma (HCC) comprising Notch3 inhibitors and a chemotherapeutic agent, methods for the preparation of said compositions and a medical treatment comprising the administration of said pharmaceutical compositions in patients in need thereof. | 2010-07-29 |
20100189776 | ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY - The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (S1): X-[(Pro) | 2010-07-29 |
20100189777 | FUNCTIONALIZED NANOCOMPARTMENTS WITH A TRANSPORT SYSTEM - The invention is directed to vesicles comprising at least one transmembrane triggered transport system for controlled transmembrane efflux and/or influx. | 2010-07-29 |
20100189779 | IN VIVO DEVICE, SYSTEM AND USAGE THEREOF - An in vivo device ( | 2010-07-29 |
20100189781 | ALKOXYALKYL S-PRENYLTHIOSALICYLATES FOR TREATMENT OF CANCER - Disclosed are alkoxyalkyl S-prenylthiosalicylates and pharmaceutical compositions containing the same and a pharmaceutically acceptable carrier. Methods for treating a human afflicted with cancer, including solid tumors, or a hematological malignancy by administering to the human in need thereof an effective amount of an alkoxyalkyl S-prenylthiosalicylate are also disclosed. | 2010-07-29 |
20100189782 | Compositions Comprising Carisoprodol and Methods of Use Thereof - The present invention provides compositions comprising carisoprodol or pharmaceutically acceptable salts, esters or derivatives thereof. In certain embodiments, the invention provides pharmaceutical compositions comprising the skeletal muscle relaxant carisoprodol and one or more additional active agents, such as one or more nonsteroidal antiinflammatory drugs (NSAIDs). The invention further provides methods of use of such compositions in preventing, alleviating and/or treating musculoskeletal pain, muscle spasms, or other non-malignant painful conditions including methods in which the circulating levels of the active pharmaceutical form of carisoprodol are controlled by use of extended- or controlled-release formulations or by strict control of dosage regimen, so as to reduce the level of somnolence observed with other muscle relaxant compositions. | 2010-07-29 |
20100189783 | RELATING TO ANTI-HIV TABLET FORMULATIONS - An anti-HIV tablet formulation comprising a core containing 0.1 to 1.5% by weight (w/w) of colloidal silicon dioxide and 0.4 to 0.9% by weight (w/w) of a lubricant, the balance of the core comprising darunavir, a disintegrant and a filler comprising a spray-dried mixture of microcrystalline cellulose and colloidal silicon dioxide, the core being optionally coated with a film coating. | 2010-07-29 |
20100189784 | Use of Alkylphophocholine in Combination with Antitumor Medication for the Treatment of Benign and Malignant Oncoses in Humans and Mammals - The invention relates to pharmaceutical compositions comprising alkylphosphocholines and antimetabolite antitumor substances. The pharmaceutical compositions of the invention are useful for the treatment of benign and malignant oncoses in humans and animals. Preferred alkylphosphocholines are described by the Formula II. | 2010-07-29 |
20100189785 | Use of D-ribose for fatigued subjects - Low doses of D-ribose raise the level of fitness and lower the perception of fatigue in baby boomers aged 45-65 who perceive themselves as fatigued. The doses range from 0.100 grams to 3.0 grams, bid, for a total of 0.200 to 6.0 grams daily. Objective measures of cardiopulmonary parameters confirm the improvement of fitness and questionnaires confirm that quality of life and mental states are improved with D-ribose administration. | 2010-07-29 |
20100189786 | CRYSTALLINE TOLTERODINE TARTARATE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - A crystalline salt of 2-[(1R)-3-[bis(1-methylethyl)amino]- | 2010-07-29 |
20100189787 | Delayed release rasagiline citrate formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 2010-07-29 |
20100189788 | Delayed release rasagiline base formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 2010-07-29 |
20100189789 | Micronized Tanaproget, Compositions, and Methods of Preparing the Same - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 2010-07-29 |
20100189790 | Delayed release rasagiline formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 2010-07-29 |
20100189791 | Delayed release rasagiline malate formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 2010-07-29 |
20100189792 | IN VIVO GENE TRANSFER METHODS FOR WOUND HEALING - The present invention relates to an in vivo method for specific targeting and transfer of DNA into mammalian repair cells. The transferred DNA may include any DNA encoding a therapeutic protein of interest. The invention is based on the discovery that mammalian repair cells proliferate and migrate into a wound site where they actively take up and express DNA. The invention further relates to pharmaceutical compositions that may be used in the practice of the invention to transfer the DNA of interest. Such compositions include any suitable matrix in combination with the DNA of interest. | 2010-07-29 |
20100189793 | ELECTROPHORETIC TRANSDERMAL DELIVERY SYSTEM - A transdermal delivery system (TDS) for administering at least one active agent through the skin. The system has a first electrode, a second electrode, and a matrix located between the first and second electrodes. The TDS contains at least one active agent which is either alkaline or acidic. The system is configured such that when applying a voltage to the electrodes, the pH of the matrix, in the case of an alkaline active agent, does not exceed the pH of the active agent and, in case of an acidic active agent, does not fall below the pH of the active agent. | 2010-07-29 |
20100189794 | NUCLEIC ACID HYDROGEL VIA ROLLING CIRCLE AMPLIFICATION - Methods and compositions are provided for producing nucleic acid-based compositions. Methods include enzyme catalyzed or nucleic acid polymer conjugation. Compositions include nucleic acid-containing hydrogels which can be elongated via rolling circle amplification. The hydrogels can encapsulate bioactive agents for drug delivery. | 2010-07-29 |
20100189795 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS - The present invention provides compositions containing one or more calcium sequestration agents and methods for topical application of such compositions to the skin to treat skin pigmentation disorders, such as melasma, post-inflammatory hyperpigmentation, pigmentation changes due to skin aging, or any other skin conditions related with normal such as skin of color or abnormal pigmentation such as hypo- or hyper-pigmentation in humans. | 2010-07-29 |
20100189796 | CRYSTALLINE FORM OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]-AMINO]-2-PYRIMIDINYL]AMINO- ]BENZONITRILE - This invention concerns polymorph I of TMC278, its use and preparation. It further concerns pharmaceutical formulations comprising this polymorph. | 2010-07-29 |
20100189797 | ORAL ANTIDEPRESSANT FORMULATION - Oral antidepressant formulation comprising a means for controlling the release of the pharmaceutically acceptable antidepressant active agent selected from the group consisting of SSRI agents, SNRIs (serotonin noradrenaline reuptake inhibitors), CRF antagonists, NK1 antagonists, NK2 antagonists, NK3 antagonists and combinations thereof, with respect to the release of the compound selected from the group consisting of acetylsalicylic acid, salts and esters of acetylsalicylic acid, diaspirin, and mixtures thereof. | 2010-07-29 |
20100189798 | CONTROL OF ERWINIA AMYLOVORA WITH VINYLGLYCINES AND BACTERIA THAT PRODUCE VINYLGLYCINES - This disclosure relates to methods of controlling | 2010-07-29 |
20100189799 | GRANULE COATED WITH URETHANE RESIN - A coated granule obtained by coating a bioactive substance-containing granule with a urethane resin obtained by reaction of an aromatic polyisocyanate with an alcohol mixture comprising a polyesterpolyol having 15 wt % or more of an oxycarbonyl structure (—O—C(═O)—) part in the molecule and a C4-C30 alkanol optionally substituted by one or more aryl groups, wherein the molar ratio of the polyesterpolyol to the alkanol is 1:1 to 100:1, is capable of controlling elution of the bioactive substance appropriately, and, the urethane resin forming the coat film shows degradability in soil. | 2010-07-29 |
20100189800 | CONTINOUS DOUBLE EMULSION PROCESS FOR MAKING MICROPARTICLES - Described herein are improved methods for microparticle encapsulation. In one aspect, the disclosed methods comprise a substantially continuous double emulsion process. In a further aspects, microparticles comprising a bioactive agent therein are made by the disclosed methods. | 2010-07-29 |
20100189801 | Drug Delivery Systems and Use Thereof - The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-Vascular Endothelial Growth Factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal. In particular, the invention provides a method for delivering the aptamer to an eye for the treatment of an ocular disorder, for example, age-related macular degeneration. | 2010-07-29 |
20100189802 | Method for treatment of vascular hyperpermeability - A method comprising preparing a vascular hyperpermeability treatment composition comprising an apoptosis regulating protein, a antioxidant, a mitochondrial modulator, a biological effector molecule, or combinations thereof in a form deliverable to a mammal; whereby an effective amount of the composition raises the threshold for apoptosis and/or prevents or lessens the occurrence of vascular hyperpermeability. A method comprising preventing hyperpermeability associated with hemorrhagic shock via preparing a composition in a form deliverable to a mammal, the composition comprising an apoptosis regulating protein, a antioxidant, a mitochondrial modulator, a biological effector molecule, or combinations thereof; and raising the threshold for apoptosis in a mammal's endothelial cells by administering an effective amount of said antioxidant; whereby said raising the threshold for apoptosis prevents said hyperpermeability. | 2010-07-29 |
20100189803 | EJACULUM OF ANIMALS AS MEDICINAL MATERIAL AND USES THEREOF IN MEDICAMENTS FOR TREATMENT OF DISEASES SUCH AS TUMORS, DEPRESSION, ETC. - Provided are ejaculum of animals as medicinal materials and uses thereof in manufacture of medicaments for treatment of various tumors, depression, senile dementia, and dermatosis. Said tumors include ovarian cancer, uterine cancer, breast cancer, esophageal cancer, stomach cancer, colon cancer, lung cancer, osteocarcinama, etc. The present medicinal material, alone or in combination with additional agents, is similar to cyclophosphamide in antineoplastic effects, which is accepted presently the most potent chemotherapeutic agent. It can inhibit the growth of tumors, not destroying the normal immune system of human. The present medicinal material of ejaculum is powdery crystal prepared by vacuum lyophilization from fresh ejaculum of animals, and it is suitable to a variety of dosage forms such as capsule or oral solution. | 2010-07-29 |
20100189804 | ANTIMICROBIAL CARBON BLACK DISPERSION - Disclosed is an antimicrobial carbon black dispersion which exhibits excellent dispersant properties and also inhibits microbial contamination when used in consumer products such as cosmetic formulations. Also disclosed are methods for producing and using the antimicrobial carbon black dispersion. | 2010-07-29 |
20100189805 | ELECTROCHEMICALLY TREATED WATER, METHOD AND DEVICE FOR THE PRODUCTION THEREOF, AND THE USE THEREOF AS A DISINFECTION AGENT - The present invention relates to electrochemically treated water, obtainable by means of a method that is characterized by the following steps: a) electrolyzing water and b) reducing the concentrations of the oxidants created in step a). The electrochemically treated water obtained in this manner is characterized by a disinfecting effect on bacteria, bacterial spores, fungi, fungal spores, viruses, prions, or mixtures thereof. The invention further relates to water, characterized in that the same has a disinfecting effect on bacteria, bacterial spores, fungi, fungal spores, viruses, algae, prions, or mixtures thereof, that it is substantially free of disinfection agents with the exception of the oxidants related to the disinfection agents, and that it has a total concentration of oxidants of less than 20 ppm. | 2010-07-29 |
20100189806 | METHOD FOR THE EFFICIENT AND CONTINUOUS GROWTH AND HARVESTING OF NUTRIENT-RICH PHYTOPLANKTON AND METHODS OF USING THE SAME - Methods of growing and harvesting multiple species of phytoplankton are disclosed herein. The method generally includes four steps, namely: (1) collecting phytoplankton seawater containing multiple species of naturally-occurring phytoplankton directly from a source of seawater; (2) adding nutrients to the phytoplankton seawater to proliferate the multiple species of naturally-occurring phytoplankton to a predetermined density; (3) separating the multiple species of naturally-occurring phytoplankton from the phytoplankton seawater to form a phytoplankton concentrate; and (4) collecting the phytoplankton concentrate such that the collected phytoplankton of the phytoplankton concentrate remain in a substantially intact cellular state. | 2010-07-29 |
20100189807 | Use of an ozone / oxygen mixture as a primary anticancer therapy via intraperitoneal insufflation - Head and neck squamous cell carcinomas (HNSCC) represent a group of metastasizing tumors with a high mortality rate in man and animals. Since the biomolecule ozone was found to inhibit growth of various carcinoma cells in vitro we here applied the highly aggressive and lethal VX2 carcinoma HNSCC tumor model of the New Zealand White rabbit to test whether ozone exerts anti-tumorous effects in vivo. Therapeutic insufflation of medical ozone/oxygen (O | 2010-07-29 |
20100189808 | SPUTUM DISSOLVING SUCTIONING SOLUTION FOR ENDOTRACHEAL AND TRACHEOSTOMY TUBES - A composition for dissolving or reducing the viscosity of sputum on a surface of a device includes an effective amount of glycerol and an effective amount of dextran sulfate in a saline solution. The effective amount of glycerol is between about 30-50% and the effective amount of dextran sulfate is between about 10-30%. The composition may further include an antimicrobial agent. | 2010-07-29 |
20100189809 | Foamable Compositions Containing Alcohol - This invention relates to compositions containing lower (C1-C4) alcohol and a polymeric fluorosurfactant formulated for being dispensed as a foam product. More particularly, the invention relates to improved compositions formulated with polymeric fluorosurfactants with pendant perfluoroalkyl side chains of a fully fluorinated chain length of C1-C7. The compositions also relate to use for personal care, such as skin sanitizing and cleansing. | 2010-07-29 |
20100189810 | Amebacidal ophthalmologic compound - An anti-amoebatic ophthalmologic compound which includes an inorganic carrier in which silver ions and hydrogen ions are added. The carrier includes silver ions and hydrogen ions in an amount of more than 1 ppm. The compound can be suspended in an aqueous solution. The aqueous solution may be controlled in a pH value of 5 to 8. The compound may be formed as a molded resinous piece containing an inorganic carrier including silver ions and hydrogen ions in an amount more than 0.01 wt %. The compound is stable, while sustaining a high anti-amoebatic property. | 2010-07-29 |
20100189811 | Biocide compositions comprising 3-methylisothiazolin-3-one and a haloalkyl sulphone - The invention relates to a biocide composition comprising, as active microbicidal components, 2-methylisothiazolin-3-one and also one or more haloalkyl sulphones, said composition being outstandingly suitable as an industrial preservative for protecting industrial products. The invention further relates to the use of haloalkyl sulphones as an additive for reducing “emissions” from compositions containing 2-methylisothiazolin-3-one. | 2010-07-29 |
20100189812 | AGENT FOR TREATING AND/OR PREVENTING OSTEOPOROSIS, COMPRISING OCEANIC MINERAL COMPONENTS - The present invention provides an agent for treating and/or preventing osteoporosis, comprising oceanic mineral components containing essential trace elements. In preparation of the agent, the oceanic mineral complex is allowed to contain as the active ingredient the residue comprising minerals chelated by treating the concentrated seawater containing organic components derived from picoplanktons living in seawater and mineral components chelated by the organic components with charcoal powder and acetic acid and then removing sodium chloride and toxic components. | 2010-07-29 |
20100189813 | Cidal formulations and methods of use - Formulated Cidal compositions containing a metal compound, an inert carrier for the metal compound and, a detergent, wherein the metal and the detergent are present at low concentrations and methods of using Cidal compositions in aqueous environments. | 2010-07-29 |
20100189814 | HERBOMINERAL FORMULATION FOR TREATING SICKLE CELL DISEASE - A herbomineral composition for the treatment of sickle cell disease is described in the present invention. The herbo mineral composition include some herbal ingredients such as Jaiphal, Sunthi, Jivanti, Haritaki, Guduchi, Shatavari, Dadima, Pippali, along with the therapeutic minerals such as Abrakha Bhasma and Loha Bhasma at suitable concentrations to obtain synergistic anti sickling activity. The composition exhibited up to 60-87% antisickling activity on RBCs in ‘vitro’ at various concentrations. Patients treated with this composition found relief from most of the severe symptoms of sickle cell disease and sickle cell anemia, and had excellent improvement in quality of life. | 2010-07-29 |
20100189815 | COLON CLEANSING COMPOSITIONS AND METHODS - A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected from the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavourings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use. | 2010-07-29 |
20100189816 | Cachexia prevention supplement - The invention provides for a nutritional composition comprising from 0.1 to 10 g of eicosapentaenoic acid or a derivative thereof based on 100 kcal of the total composition; and from 0.1 to 10 g of a phytochemical or a mixture thereof based on 100 kcal of the total composition, for a use as a medicament for the treatment and/or prevention of cachexia and/or anorexia. The composition is particularly useful in the prevention of cachexia and is administered almost without any additional macronutrients in order to avoid a negative impact on the general diet of the patient. | 2010-07-29 |
20100189817 | Treating Glaucoma - Provided herein are methods of protecting all or a portion of the optic nerve fiber layer within the optic nerve/lamina cribrosa (ONLC) complex in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and protecting all or a portion of the optic nerve fiber layer within the ONLC of the individual. In a particular embodiment, the invention is directed to methods of treating glaucoma in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucoma in the individual. In yet another embodiment, the invention is directed to methods of treating glaucomatous optic neuropathy in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucomatous optic neuropathy in the individual. The method can further comprise administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's lamina cribrosa (LC). | 2010-07-29 |
20100189818 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL - Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent. | 2010-07-29 |
20100189819 | NEURO-DEGENERATIVE INHIBITOR, NEURO-ENDOCRINE MODULATOR, AND NEURO-CEREBRAL METABOLISM ENHANCER - Neuro-metabolic and endocrine-function regulating/modulating compositions, are disclosed. The compositions of the present invention comprise Selegiline Hydrochloride, Procaine Hydrochloride, Vinpocetine, trimethylglycine, and an ingredient selected from a group consisting of N-nicotinoyl-gamma-aminobutyric acid (N-GABA), niacin, niacinamide, gamma-aminobutyric acid (GABA), and combinations thereof. Methods of using the compositions, compositions, and compositions of the present invention are also disclosed. | 2010-07-29 |
20100189820 | Composition and Methods for Maintaining Skeletal Muscle Androgen Receptivity - A nutritional composition comprising at least L-carnitine fumarate, red wine extract, and saw palmetto extract is provided to maintain skeletal muscle androgen receptivity, via simultaneous increase in the availability of androgen receptors and improved availability of testosterone, while at the same time reducing some of the adverse effects of increased testosterone levels. A method of same is also provided. The present invention further comprises one or more of N-acetyl L-Carnitine, Ubidecarenone (coenzyme Q10), Idebenone, Decylubiquinone, Astaxanthin, and Ginsenoside Rb1. | 2010-07-29 |
20100189821 | COMPOSITION OF SKIN EXTERNAL APPLICATION CONTAINING GINSENG BERRY EXTRACTS - Disclosed herein is a. skin external composition containing ginseng berry extract. More specifically, disclosed is a skin external composition, which contains, as an active ingredient, ginseng berry extract having the specific components and compositions, among the above-ground parts of ginseng, and thus promotes the production of collagen in the skin, shows an MMP-I inhibitory effect and, at the same time, has skin-aging inhibitory and wrinkle-reducing effects, resulting from antioxidant effects and DNA damage-protecting effects. Also disclosed is a skin external composition, which contains, as an active ingredient, ginseng berry extract, which has a skin whitening effect resulting from the effects of inhibiting melanin production and reducing pigmentation caused by UV radiation, the effects of relieving dry skin symptoms and atopic symptoms by inducing and maintaining the normal differentiation of skin keratinocytes, the effect of relieving acne and skin troubles by the regulation of sebum secretion and an anti-inflammatory effect, and makes complexion ruddy through the improvement of peripheral blood circulation to make the skin clean and clear. Also disclosed is a food composition for reducing and preventing obesity, which contains, as an active ingredient, ginseng berry extract, which increases the expression of a carnitine palmitoyl transterase-1 (CPT-I) gene, serves to transport fatty acids into mitochondria in fatty acid oxidation and promotes fat oxidation. | 2010-07-29 |
20100189822 | DEGRADATION INHIBITOR FOR FLAVOR OR AROMA - The invention provides a deterioration inhibitor with an even stronger effect than the prior art against deterioration of flavors and fragrances in foods and beverages or cosmetics, which is attributed to heat, light and the like, and especially against production of deterioration odors derived from citral. | 2010-07-29 |
20100189823 | Method For Preparing A Hypericum Extract In Neem Oil And A Substance So Obtained - A method for making a | 2010-07-29 |
20100189824 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF - The invention provides novel saponin mixtures and compounds which are isolated from the species | 2010-07-29 |
20100189825 | Pharmaceutical composition for treating rheumatism, and method of making same - A pharmaceutical composition for the treatment of rheumatism and a method of preparing it are provided. The composition consists of an alcoholic extract of 1-4 parts by weight | 2010-07-29 |
20100189826 | Extracts and Compounds for Inhibiting Tyrosinase Activity - The invention provides a | 2010-07-29 |
20100189827 | ANTIVIRAL COMPOSITION COMPRISING ALNUS JAPONICA EXTRACTS - Antiviral compositions including | 2010-07-29 |
20100189828 | Medicinal herbal composition for treating infection - Herbal compositions derived from Kenyan plants are provided for the treatment of HIV and other infectious diseases. The herbal compositions can include the extracts of up to 14 plants, including the root of | 2010-07-29 |
20100189829 | COCOA EXTRACT AND USE THEREOF - A cocoa extract obtainable by the extraction of non-defatted cocoa beans which have not been fermented or have been allowed to ferment for no more than three days, having a polyphenol content of more than 25% by weight, may be used in the treatment or prophylaxis of a condition selected from dysphoria, depression, anxiety, sleep disorders, gastric motility disorders, sexual dysfunction, brain trauma, memory loss, appetite disorders, bulimia, substance abuse, alcoholism, tobacco addiction, obsessive-compulsive disease, panic disorder, premenstrual syndrome, and migraine. | 2010-07-29 |
20100189830 | Sweet Gum Fruit Extract as a Therapeutic Agent - Sweet gum ( | 2010-07-29 |
20100189831 | Machine for horizontally manufacturing flexible sheet material packagings with outside chamber - Machine for horizontally manufacturing flexible sheet material packagings, including an area for feeding a continuous web of flexible sheet material, a preforming area including an area for folding the bottom wall of said packaging and a welding area, an area for filling said packagings, an area for outputting said packagings, a first chemical decontamination treatment area using a gas, arranged between the preforming area and the filling area, and an outside chamber that surrounds said machine at least partially and is depressed with respect to said first area. The outside chamber acts as an additional barrier between the first area and the outside. | 2010-07-29 |
20100189832 | APPARATUS FOR FEEDING MOLTEN RESIN - [Problems] To provide an apparatus for feeding molten resin capable of preventing the adhesion of matters on the holding units for holding the molten resin, and of shortening the cycle for cleaning the holding units. | 2010-07-29 |
20100189833 | Equipment for Producing Molecularly Bioriented Tubular Profiles and Corresponding Method - The equipment consists of a mould ( | 2010-07-29 |
20100189834 | IMPRINTING APPARATUS - The present invention provides an imprinting apparatus in which stampers, after a transfer step, can be readily and quickly detached from a substrate and an atmosphere in the imprinting apparatus is kept clean. The imprinting device has an ejecting mechanism for separating a recording medium substrate from a first stamper and a second stamper the ejecting mechanism being formed including a sleeve and a coil spring that are movably provided in a movable die base with an exhausting duct, and also including a sleeve and a coil spring that are movably provided in a fixed die base with an exhausting duct. | 2010-07-29 |
20100189835 | HARD COATING FILM, MATERIAL COATED WITH HARD COATING FILM AND DIE FOR COLD PLASTIC WORKING AND METHOD FOR FORMING HARD COATING FILM - The present invention provides hard coating film which excels conventional surface coating layer in wear resistance, has lower frictional coefficient and better slidability, a material coated with the hard coating film, a die for cold plastic working, and a method for forming the hard coating film. The hard coating film according to the present invention is a hard coating film comprising (Nb | 2010-07-29 |
20100189836 | MICROPATTERN TRANSFER DEVICE - In a micropattern transfer device, a stamper on which a fine indented pattern is formed is brought into contact with a material to be transferred, and the fine indented pattern on the stamper is transferred onto a surface of the material to be transferred. The micropattern transfer device includes a holding mechanism which holds an entire outer circumferential portion of the material to be transferred. The holding mechanism holds the material to be transferred such that a distance between the material to be transferred and the stamper is substantially equal to or shorter than a distance between the holding mechanism and the stamper. | 2010-07-29 |
20100189837 | System and Method for Depositing Thin Layers on Non-Planar Substrates by Stamping - An elastomeric stamp is used to deposit material on a non-planar substrate. A vacuum mold is used to deform the elastomeric stamp and pressure is applied to transfer material from the stamp to the substrate. By decreasing the vacuum applied by the vacuum mold, the elasticity of the stamp may be used to apply this pressure. Pressure also may be applied by applying a force to the substrate and/or the stamp. The use of an elastomeric stamp allows for patterned layers to be deposited on a non-planar substrate with reduced chance of damage to the patterned layer. | 2010-07-29 |
20100189838 | INJECTION HEAD FOR A CORRUGATOR FOR THE PRODUCTION OF PLASTICS PIPES - An injection head ( | 2010-07-29 |
20100189839 | IMPRINT MOLD - An imprint mold including a substrate of transparent material having a first principal surface having a pattern region and a second principal surface; a first light shielding film provided on the first principal surface, along a periphery of the pattern region; and a second light shielding film provided on the second principal surface, having an opening including an opposite region to the pattern region, a part of the second light shielding film opposite to the first light shielding film. In a cross section perpendicular to the substrate, the maximum incident angle of the light for curing a transfer layer to the second principal surface is less than an angle between a perpendicular line of the second principal surface and a line connecting an end of the second light shielding film on a side of the opening and a farthest end of the first light shielding film from the pattern region. | 2010-07-29 |